Welcome to our dedicated page for Immuron SEC filings (Ticker: IMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immuron Limited’s SEC filings document its foreign private issuer disclosures and ASX announcements furnished on Form 6-K. The filings include half-year financial reports, strategic updates and investor presentations describing the company’s oral polyclonal antibody platform, Hyper-Immune products, Travelan®, ProIBS®, and clinical programs for gastrointestinal infectious diseases.
The filing record also covers shareholder meeting results, small-holding share sale facility disclosures, R&D Tax Incentive notices, regional sales updates, and governance authorizations by the board. These documents provide formal disclosures on operating results, research and development funding, ordinary-share matters, and public-company reporting obligations for IMRN’s ASX and Nasdaq-traded securities.
Immuron Limited (IMRN) filed a Form 20-F presenting a biotech group focused on hyper-immune products and R&D-stage therapeutics, including its commercial product Travelan.
Reported full-year figures show revenue lines including A$2,599,458 of grant or other income and product sales components (e.g., Travelan US A$1,658,336; Canada A$378,706). Research and development expense was A$3,597,296 and general operating expenses contributed to net operating losses. The group recorded a net decrease in cash and cash equivalents of A$8,837,614 from a starting cash balance of A$11,657,315. The balance sheet shows total assets of A$10,437,270 and total liabilities of A$2,059,491.
Operationally, Immuron disclosed multiple granted patents across jurisdictions and recent PCT filings, continued investment in clinical programs, and an At-The-Market facility raising A$2,809,177 (US$1,822,322) to support at least the next 12 months. The financial statements are prepared on a going concern basis.
Immuron Limited submitted a Form 6-K as a foreign private issuer, mainly to furnish investors with materials already released on the Australian Securities Exchange. The filing attaches two September 2, 2025 announcements: an Appendix 4E Preliminary Final Report and an FY25 results presentation. These exhibits provide the detailed financial and operational results for the fiscal year ended FY25, while the Form 6-K itself clarifies that this information is furnished to U.S. markets but is not deemed filed under the Exchange Act or automatically incorporated into other U.S. securities filings.
Immuron Limited submitted a Form 6-K as a foreign private issuer to furnish recent announcements made to the Australian Securities Exchange. The filing notes that the company published two public notices on August 26, 2025, including one titled “Immuron partners with InvestorHub,” which is attached as Exhibit 99.2.
The company clarifies that this Form 6-K and its exhibit are furnished, not filed, under U.S. securities laws and will only be incorporated into other securities filings if specifically referenced.
Immuron Limited filed a Form 6-K as a foreign private issuer for August 2025 to furnish two announcements previously published on the Australian Securities Exchange. These ASX notices, titled Appendix 3G, are attached, including Exhibit 99.2, a notification regarding unquoted securities for IMC.
Immuron Limited furnished a Form 6-K reporting that it published two public notices to the Australian Securities Exchange titled "Emerging Growth Conference Presentation". The filing states that a copy of the presentation is attached to the Form 6-K as Exhibit 99.2.
The Form 6-K clarifies that this submission and the attached exhibit are furnished for information only and are not deemed to be "filed" under the U.S. Exchange Act, and therefore are not incorporated by reference into other securities filings except by explicit reference. The report is signed on behalf of the company by its Company Secretary.